Blueprint Medicines, a preclinical biotech developing kinase inhibitors for cancer and genetic diseases, raised $147 million by offering 8.1 million shares (upsized from 7.2 million shares) at $18, above the range of $15 to $17. Blueprint Medicines plans to list on the NASDAQ under the symbol BPMC. Blueprint Medicines initially filed confidentially on 2/19/2015. Goldman Sachs and Cowen & Company acted as lead managers on the deal.
